Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer (ACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01593293
Recruitment Status : Unknown
Verified May 2012 by Sang-We Kim, Asan Medical Center.
Recruitment status was:  Recruiting
First Posted : May 8, 2012
Last Update Posted : May 8, 2012
Eli Lilly and Company
Korean Cancer Study Group
Information provided by (Responsible Party):
Sang-We Kim, Asan Medical Center

Brief Summary:
The number of NSCLC patients above 70 years of age who are non-squamous histology is increasing around the world. Although previous guidelines often recommend single agent therapy for NSCLC, recent studies suggest that platinum doublets may be better than standard monotherapy in elderly. We hypothesize that for elder patients (≥70 years of age) with non-squamous NSCLC, pemetrexed and carboplatin is more effective than pemetrexed monotherapy in terms disease progression, overall survival, and quality of life and tolerability.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: PemCarbo Drug: Pem only Phase 3

Detailed Description:

The treatment of NSCLC in elderly has been subject to discussion for years. While platinum doublets consisting of cisplatin or carboplatin and another cytotoxic agent demonstrate a survival advantage compared with single agents generally, evidence of treatment efficacy for patients with diminished performance status (PS) or with age older than 70 years is limited. Guidelines from the US and Europe have preferred single-agent chemotherapy for the elderly and PS 2 patients. However, increasing studies are exploring this issue and presenting data that favour doublet therapy. The addition of carboplatin to paclitaxel and cisplatin to docetaxel have shown evidence that patients over 70 benefit more in face of increased toxicities.

This study is designed to be multi-center, open-label, prospective, randomized, two-arm, parallel, phase III trial of elderly patients(≥70 years old) with metastatic non-squamous NSCLC (Stage IV by AJCC 7th) who have not received prior systemic chemotherapy or biological therapy. Approximately 266 patients will be enrolled into the trial. This study compares the doublet therapy of pemetrexed (500 mg/m2) and carboplatin (AUC 5 mg/mL*min) administered intravenously every 21 days for 4 cycles followed by pemetrexed (500 mg/m2) every 21 days for maintenance therapy (Arm A) to single therapy of pemetrexed (500 mg/m2) every 21 days till progression or unacceptable toxicity (Arm B). Pemetrexed will be administered with vitamin B12 and folate supplements.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 266 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Study Start Date : March 2012
Estimated Primary Completion Date : November 2014
Estimated Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Active Comparator: PemCarbo
Pemetrexed/Carboplatin arm
Drug: PemCarbo
Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
Other Name: Alimta: brand name of Pemetrexed

Active Comparator: Pem only
Pemetrexed arm
Drug: Pem only
Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
Other Name: Alimta: brand name of pemetrexed

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: The study lasts for 30 months of which subject accrual occurs in the first 24 months ]
    To compare the progression free survival of elderly patients (≥70 years old) with non-squamous NSCLC receiving doublet of carboplatin and pemetrexed to patients receiving pemetrexed alone.

Secondary Outcome Measures :
  1. Objective response rate, Overall survival, Safety and Quality of life [ Time Frame: The study lasts for 30 months of which subject accrual occurs in the first 24 months ]
    1. To compare the following efficacy variables between treatment arms:

      • Objective response rate
      • Overall survival
    2. To compare the safety and adverse event profile between treatment arms
    3. To assess the impact of treatment on patient-rated quality of life (FACT-L)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed advanced non-squamous non-small cell lung cancer (stage IV, AJCC 7th)
  • Age 70 years old or older
  • Eastern Cooperative Oncology Group performance status 0-1
  • Measurable or assessable disease as defined by RECIST 1.1
  • Estimated life expectancy of more than 3 months
  • Adequate bone marrow function(Absolute Neutrophil Count (ANC) ≥ 1,500/µL, platelets ≥ 100,000/µL, hemoglobulin ≥ 9 g/dL)
  • Adequate renal function: creatinine < 1 x upper normal limit (UNL) or creatinine clearance(Ccr) using Cockroft and Gault formula ≥45 ml/min
  • Adequate hepatic function: bilirubin < 1.5 x UNL, AST/ALT levels < 3 x UNL, alkaline phosphatase < 3 x UNL (except in case of bone metastasis without any liver disease)
  • Written informed consent

Exclusion Criteria:

  • Prior systemic chemotherapy or biological therapy
  • Contraindication to any drug contained in the chemotherapy regimen
  • Clinically significant third-space fluid collections (e.g. pleural effusion and pericardial effusion) that cannot be controlled by drainage or other procedures prior to study enrollment
  • Active infection which would compromise the patient's ability to tolerate treatment
  • Requirement for major surgery within 4 weeks of study entry
  • Myocardial infarction, uncontrolled arrhythmias, symptomatic angina pectoris, cardiac failure within the previous 6 months
  • Unable to discontinue administration of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs); Aspirin or NSAIDs should be at least 5 days before pemetrexed administration
  • Presence or history of CNS metastasis (except if adequately treated and is not receiving steroid therapy for at least 2 weeks; at least 2 weeks for whole brain radiation or at least 1 week for gamma knife surgery)
  • Peripheral neuropathy ≥ grade 2
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin, cured carcinoma in-situ of uterine cervix and cured thyroid malignancy
  • Pregnant or lactating women, women of childbearing potential not employing adequate contraception
  • Other serious illness or medical conditions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01593293

Layout table for location contacts
Contact: Sang-We Kim, M.D. 82-2-3010-3215

Layout table for location information
Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 138-736
Contact: Sang-We Kim, M.D.    82-2-3010-3215   
Sponsors and Collaborators
Asan Medical Center
Eli Lilly and Company
Korean Cancer Study Group
Layout table for investigator information
Principal Investigator: Sang-We Kim, M.D. Asan Medical Center
Layout table for additonal information
Responsible Party: Sang-We Kim, Professor, Asan Medical Center Identifier: NCT01593293    
Other Study ID Numbers: AMC 2011-0857
AMC 2011-0857 ( Other Identifier: Asan Medical Center )
First Posted: May 8, 2012    Key Record Dates
Last Update Posted: May 8, 2012
Last Verified: May 2012
Keywords provided by Sang-We Kim, Asan Medical Center:
Elderly patients
Non-squamous Non-small Cell Lung Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors